Recent
Advances
The
routine use of MR guided stereotactically placed neuro-surgical lesions and the
increasing availability of the gamma knife offer more precise procedures with
objectively quantifi-able lesions. High resolution structural MRI studies are
being used to track volumetric changes local and distal to the lesions (Rauch et al., 2000) and PET studies are
providing informa-tion about blood flow and regional metabolism that may serve
as predictors of response (Rauch et al.,
2001). Recordings in implicated brain structures such as the cingulum (similar
to intracortical recordings and microdialysis in the temporal lobe in surgical
epilepsy patients) may provide useful additional in-formation. Strategies such
as magnetic resonance spectroscopy (MRS) and newer methods such as diffusion
tensor imaging (DT-MRI) can provide information about regional neurochem-istry
and white matter tract integrity, respectively. They offer the exciting
possibility of collecting valuable neurobiological data, which may aid in
monitoring changes as well as predict-ing response.
Recently,
several new experimental strategies have emerged and are being investigated in
refractory OCD and MDD. These are invasive modalities currently being offered
only in the context of research studies and thus have not been proven or
approved for treatment. They are included in this discussion for the sake of
completion.
Deep
brain stimulation (DBS) involves stimulation of target regions via
stereotactically placed electrodes that can be pro-grammed to deliver low
voltage electrical stimulation to modulate transmission of specific brain
pathways. While DBS of different regions has been experimentally investigated
for treatment-refrac-tory pain syndromes, movement disorders and seizure
disorders, only DBS for treatment-refractory Parkinson’s disease or essential
tremor is currently FDA approved in the USA. Recently following a preliminary
report of deep brain stimulation in the anterior limb of the internal capsule
in four patients with treatment-refractory OCD (Nuttin et al., 1999), a few specialized centers in the world (including
the USA) are conducting ongoing controlled studies of DBS in
treatment-refractory OCD patients. Nuttin and colleagues described four
patients with treatment-refractory OCD who un-derwent DBS with bilateral
stereotactically implanted quadripolar electrodes in the anterior limb of the internal
capsule (instead of an-terior capsulotomy) and reported “beneficial effects” in
three of the four patients. It is important to note that this remains an
experimen-tal procedure at this stage for treatment-refractory OCD.
Neverthe-less these developments offer the exciting possibility of reversible
“lesions” as well as ethically justifiable sham procedures (controls can be
implanted but the stimulation not turned on or at lower volt-age undetectable
by the patient who can subsequently receive the benefit of the treatment)
(Greenberg, personal communication).
Vagal
nerve stimulation, used formerly only as an FDA approved treatment strategy for
some patients with drug-resistant, partial-onset epilepsy due to its seizure
attenuating effects, has been ap-proved for use in treatment of depression.
Related Topics
Privacy Policy, Terms and Conditions, DMCA Policy and Compliant
Copyright © 2018-2023 BrainKart.com; All Rights Reserved. Developed by Therithal info, Chennai.